FLGT PE Ratio & Valuation,Is FLGT Overvalued

FLGT Relative Valuation

FLGT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, FLGT is overvalued; if below, it's undervalued.

Historical Valuation

Fulgent Genetics Inc (FLGT) is now in the Fair zone, suggesting that its current forward PS ratio of 0.00 is considered Fairly compared with the five-year average of -35.51. The fair price of Fulgent Genetics Inc (FLGT) is between NaN to NaN according to relative valuation methord.

Relative Value

Fair Zone

NaN-NaN

Current Price：26.92

Fair

-122.62

-9.65

EV/EBITDA

Fulgent Genetics Inc. (FLGT) has a current EV/EBITDA of -9.65. The 5-year average EV/EBITDA is 7.46. The thresholds are as follows: Strongly Undervalued below -14.25, Undervalued between -14.25 and -3.40, Fairly Valued between 18.31 and -3.40, Overvalued between 18.31 and 29.16, and Strongly Overvalued above 29.16. The current Forward EV/EBITDA of -9.65 falls within the Undervalued range.

-0.88

EV/EBIT

Fulgent Genetics Inc. (FLGT) has a current EV/EBIT of -0.88. The 5-year average EV/EBIT is -0.66. The thresholds are as follows: Strongly Undervalued below -44.04, Undervalued between -44.04 and -22.35, Fairly Valued between 21.03 and -22.35, Overvalued between 21.03 and 42.72, and Strongly Overvalued above 42.72. The current Forward EV/EBIT of -0.88 falls within the Historic Trend Line -Fairly Valued range.

2.41

Fulgent Genetics Inc. (FLGT) has a current PS of 2.41. The 5-year average PS is 3.16. The thresholds are as follows: Strongly Undervalued below 0.93, Undervalued between 0.93 and 2.05, Fairly Valued between 4.28 and 2.05, Overvalued between 4.28 and 5.39, and Strongly Overvalued above 5.39. The current Forward PS of 2.41 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/OCF

Fulgent Genetics Inc. (FLGT) has a current P/OCF of 0.00. The 5-year average P/OCF is -11.24. The thresholds are as follows: Strongly Undervalued below -79.81, Undervalued between -79.81 and -45.52, Fairly Valued between 23.05 and -45.52, Overvalued between 23.05 and 57.33, and Strongly Overvalued above 57.33. The current Forward P/OCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

0.00

P/FCF

Fulgent Genetics Inc. (FLGT) has a current P/FCF of 0.00. The 5-year average P/FCF is -17.24. The thresholds are as follows: Strongly Undervalued below -129.09, Undervalued between -129.09 and -73.16, Fairly Valued between 38.69 and -73.16, Overvalued between 38.69 and 94.62, and Strongly Overvalued above 94.62. The current Forward P/FCF of 0.00 falls within the Historic Trend Line -Fairly Valued range.

Fulgent Genetics Inc (FLGT) has a current Price-to-Book (P/B) ratio of 0.74. Compared to its 3-year average P/B ratio of 0.63 , the current P/B ratio is approximately 16.56% higher. Relative to its 5-year average P/B ratio of 1.34, the current P/B ratio is about -45.10% higher. Fulgent Genetics Inc (FLGT) has a Forward Free Cash Flow (FCF) yield of approximately 0.00%. Compared to its 3-year average FCF yield of 1.75%, the current FCF yield is approximately -100.00% lower. Relative to its 5-year average FCF yield of 9.11% , the current FCF yield is about -100.00% lower.

0.74

P/B

Median3y

0.63

Median5y

1.34

-2.37

FCF Yield

Median3y

1.75

Median5y

9.11

Competitors Valuation Multiple

The average P/S ratio for FLGT's competitors is , providing a benchmark for relative valuation. Fulgent Genetics Inc Corp (FLGT) exhibits a P/S ratio of , which is NaN% above the industry average. Given its robust revenue growth of 17.18%, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

Revenue Growth

Market Cap

Performance Decomposition

Market capitalization of FLGT increased by 45.75% over the past 1 year. The primary factor behind the change was an decrease in P/E Change from -10.16 to -19.20.

The secondary factor is the Revenue Growth, contributed 17.18%to the performance.

Overall, the performance of FLGT in the past 1 year is driven by P/E Change. Which is more unsustainable.

17.18%

71.74M → 84.07M

Revenue Growth

-60.35%

-20.48 → -8.12

Margin Expansion

88.92%

-10.16 → -19.20

P/E Change

45.75%

18.47 → 26.92

Mkt Cap Growth

People Also Watch

Frequently Asked Questions

Is Fulgent Genetics Inc (FLGT) currently overvalued or undervalued?

What is Fulgent Genetics Inc (FLGT) fair value?

FLGT's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average , adjusted by weights. The fair price of Fulgent Genetics Inc (FLGT) is between NaN to NaN according to relative valuation methord.

How does FLGT's valuation metrics compare to the industry average?

What is the current P/B ratio for Fulgent Genetics Inc (FLGT) as of Dec 16 2025?

As of Dec 16 2025, Fulgent Genetics Inc (FLGT) has a P/B ratio of 0.74. This indicates that the market values FLGT at 0.74 times its book value.

What is the current FCF Yield for Fulgent Genetics Inc (FLGT) as of Dec 16 2025?

As of Dec 16 2025, Fulgent Genetics Inc (FLGT) has a FCF Yield of 0.00%. This means that for every dollar of Fulgent Genetics Inc’s market capitalization, the company generates 0.00 cents in free cash flow.

What is the current Forward P/E ratio for Fulgent Genetics Inc (FLGT) as of Dec 16 2025?

As of Dec 16 2025, Fulgent Genetics Inc (FLGT) has a Forward P/E ratio of -122.62. This means the market is willing to pay $-122.62 for every dollar of Fulgent Genetics Inc’s expected earnings over the next 12 months.

What is the current Forward P/S ratio for Fulgent Genetics Inc (FLGT) as of Dec 16 2025?

As of Dec 16 2025, Fulgent Genetics Inc (FLGT) has a Forward P/S ratio of 0.00. This means the market is valuing FLGT at $0.00 for every dollar of expected revenue over the next 12 months.

FLGT Valuation